Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Rao L. Divi, PhD

Program Director
Methods and Technologies Branch, Epidemiology and Genomics Research Program

Telephone: 240-276-6913

  • PhD - Biochemistry, Osmania University
  • MSc - Biochemistry, Andhra University
  • BSc - Organic Chemistry, Andhra University
Contact for questions about:
  • Methods and technologies
  • Technologies for low-resource areas
  • Assessment methods of immune function
  • Technologies to characterize natural anti-tumor immunity at population scale


Rao L. Divi, PhD, is a program director in the Methods and Technologies Branch (MTB). His responsibilities include managing a research portfolio and initiatives that focus on the development of methods and technologies to address epidemiologic data collection, study design and analysis, and validation of emerging technologies for application across the cancer control continuum. He is the EGRP representative to the International Lymphoma Epidemiology Consortium (InterLymph); the Chronic Lymphocytic Leukemia Research Consortium (CRC); the Identification of Men with a Genetic Predisposition to ProstAte Cancer: Targeted screening in BRCA1 and BRCA2 mutation carriers and controls (IMPACT) Consortium; and the Prevention and Observation of Surgical Endpoints and Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (PROSE-Modifiers Studies) (Collaborative Studies of BRCA 1/2 Mutation Carriers) Consortium. Dr. Divi is also a member of the InterLymph Coordinating Committee.

Dr. Divi is a member of the NIH Rapid Acceleration of Diagnostics (RADx) Initiative management team. RADx was launched to accelerate innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. He also serves on the management team of NIH Point-of-Care Technologies Research Network (POCTRN).

In addition, Dr. Divi is the co-program director and contact person for funding opportunities on Assay Validation of High Quality Markers for Clinical Studies in Cancer (PAR-20-313 and PAR-20-314), Co-infection and Cancer (PAR 23-055 and PAR-23-056), and the NIH Bioengineering Research Partnerships Program (PAR-22-242 and PAR-22-243).

Dr. Divi joined EGRP in 2008 from NCI's intramural Laboratory of Cancer Biology and Genetics. Since 1997, he had been a member of the Laboratory's Carcinogen-DNA Interactions Section, where he focused on understanding the genotoxicity and carcinogenicity of cisplatin, tamoxifen, PHIP, and polycyclic aromatic hydrocarbons, as well as the mitochondrial toxicity of antiretroviral drugs. A significant portion of Dr. Divi's work focused on identification of molecular markers, development of methods and technologies for the markers, and validation of those markers through intra- and interlaboratory collaborations. He used these molecular markers in collaborative studies that assessed risk in humans and animal models.

Prior to joining NCI, Dr. Divi worked for four years at the National Center for Toxicological Research, which is the research arm of the U.S. Food and Drug Administration (FDA), in Jefferson, AR. Here he conducted research on the antithyroid activity of drugs and environmental toxicants. He also worked for a year on an International Atomic Energy Agency project on health effects of trace elements.